RESUMEN
In August 2012, we reported (VersMed 1/2014, S. 9) the results for the first 12 months following implementation of AWMF guideline 051-029 in the medical assessment of mental health diseases with a view to sick pay and supplementary disability insurance (BU). Today we provide an update of the experience gained in the last three years. We are glad to report that the results have remained stable.
Asunto(s)
Evaluación de la Discapacidad , Determinación de la Elegibilidad/normas , Seguro por Discapacidad/economía , Trastornos Mentales/diagnóstico , Trastornos Mentales/economía , Ausencia por Enfermedad/economía , Determinación de la Elegibilidad/economía , Alemania , Adhesión a Directriz/estadística & datos numéricos , Seguro por Discapacidad/normas , Guías de Práctica Clínica como AsuntoRESUMEN
In the years 2005-2015, a leading assessment institute conducted numerous assessments on behalf of two major German private health insurance companies concerning the necessity of prescriptive therapies and remedies. The findings are presented in this article, and the results vary significantly, depending on the prescriptive therapy assessed.
Asunto(s)
Testimonio de Experto/legislación & jurisprudencia , Seguro de Salud/legislación & jurisprudencia , Programas Nacionales de Salud/legislación & jurisprudencia , Terapia Ocupacional/legislación & jurisprudencia , Modalidades de Fisioterapia , Prescripciones , Privatización/legislación & jurisprudencia , Psicoterapia/legislación & jurisprudencia , Resultado del Tratamiento , Alemania , Humanos , Procedimientos InnecesariosRESUMEN
The assessment of mental health for sick pay and disability supplementary insurance (BUZ) has, in comparison to specialties like internal medicine or orthopaedic surgery, a traditionally low selectivity between BU/AF (sick pay) or BU/Non-BU (BUZ). Reliability, validity and objectivity were low. The appraisals were created individually according to the designee's experience and were very inhomogeneous in structure and quality. The publication of the guideline 051-029 in March 2012 provides improved grounds for the assessment of patients. In this article, we describe our experiences for the first twelve months after the implementation of the guideline.
Asunto(s)
Evaluación de la Discapacidad , Testimonio de Experto/normas , Seguro por Accidentes/normas , Trastornos Mentales/diagnóstico , Trastornos Mentales/economía , Guías de Práctica Clínica como Asunto , Ausencia por Enfermedad/legislación & jurisprudencia , Testimonio de Experto/legislación & jurisprudencia , Alemania , Humanos , Seguro por Accidentes/legislación & jurisprudencia , Seguro por DiscapacidadRESUMEN
Cancer-related Fatigue (CrF) is a common disease that occurs in connection with oncological disease, characterised by feelings of fatigue and lack of energy and even after successful primary treatment of the underlying disease as an independent event in impairment of the health and quality of life as well as the ability to work can lead to vocational disability. There are indications that the affected persons suffer more from CrF than from pain.